Polpharma Biologics Group BV, Formycon AG and Bioeq AG, have announced that the U.S. Food and Drug Administration (FDA) has approved Cimerli (ranibizumab-eqrn), a biosimilar product interchangeable with Lucentis (ranibizumab injection).   FYB201 was developed by Bioeq, a Joint Venture between Polpharma Biologics and Formycon. End of the year 2019, Coherus BioSciences Inc. entered into a license agreement for the exclusive commercialization of FYB201 under the brand name Cimerli in the U.S.   ...